296 related articles for article (PubMed ID: 33345342)
1. Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review.
Yang Y; Liu J; Yang K; Ma Y; Fu S; Tang X; Wang Y; Zhou L
J Clin Pharmacol; 2021 Mar; 61(3):282-297. PubMed ID: 33345342
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
4. Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
Vardarli I; Tan S; Brandenburg T; Weidemann F; Görges R; Herrmann K; Führer D
J Clin Endocrinol Metab; 2024 Mar; 109(4):1132-1144. PubMed ID: 37967245
[TBL] [Abstract][Full Text] [Related]
5. The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis.
Zhao P; Zhao T; Yu L; Ma W; Liu W; Zhang C
Front Oncol; 2024; 14():1381250. PubMed ID: 38756658
[TBL] [Abstract][Full Text] [Related]
6. How we treat endocrine complications of immune checkpoint inhibitors.
Paschou SA; Stefanaki K; Psaltopoulou T; Liontos M; Koutsoukos K; Zagouri F; Lambrinoudaki I; Dimopoulos MA
ESMO Open; 2021 Feb; 6(1):100011. PubMed ID: 33399077
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
de Filette J; Andreescu CE; Cools F; Bravenboer B; Velkeniers B
Horm Metab Res; 2019 Mar; 51(3):145-156. PubMed ID: 30861560
[TBL] [Abstract][Full Text] [Related]
8. The side effects of immune checkpoint inhibitor therapy on the endocrine system.
Goyal I; Pandey MR; Sharma R; Chaudhuri A; Dandona P
Indian J Med Res; 2021 Apr; 154(4):559-570. PubMed ID: 35435341
[TBL] [Abstract][Full Text] [Related]
9. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
10. [Endocrine side effects of cancer immunotherapy].
Kroiß M; Schilling B; Deutschbein T
Dtsch Med Wochenschr; 2020 Dec; 145(24):1736-1741. PubMed ID: 33254246
[TBL] [Abstract][Full Text] [Related]
11. Endocrine toxicities of immune checkpoint inhibitors.
Wright JJ; Powers AC; Johnson DB
Nat Rev Endocrinol; 2021 Jul; 17(7):389-399. PubMed ID: 33875857
[TBL] [Abstract][Full Text] [Related]
12. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.
Abdel-Rahman O; ElHalawani H; Fouad M
Future Oncol; 2016 Feb; 12(3):413-25. PubMed ID: 26775673
[TBL] [Abstract][Full Text] [Related]
13. Endocrine side effects of immune checkpoint inhibitors.
Cardona Z; Sosman JA; Chandra S; Huang W
Front Endocrinol (Lausanne); 2023; 14():1157805. PubMed ID: 37251665
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis.
Lu J; Li L; Lan Y; Liang Y; Meng H
Cancer Med; 2019 Dec; 8(18):7503-7515. PubMed ID: 31679184
[TBL] [Abstract][Full Text] [Related]
15. Thyroid Dysfunction in Non-Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta-Analysis.
Lin L; Yang F; Lin G; Chen X
J Clin Pharmacol; 2023 Feb; 63(2):210-218. PubMed ID: 36083133
[TBL] [Abstract][Full Text] [Related]
16. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
Santos MJ
Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
[TBL] [Abstract][Full Text] [Related]
17. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
18. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
Del Rivero J; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL
Oncologist; 2020 Apr; 25(4):290-300. PubMed ID: 32297436
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
[TBL] [Abstract][Full Text] [Related]
20. Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians.
Deligiorgi MV; Panayiotidis MI; Trafalis DT
Immunotherapy; 2020 May; 12(7):481-510. PubMed ID: 32345074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
